Zhejiang Medicine Signs Long-Term Supply Contract With Hospira
This article was originally published in PharmAsia News
Executive Summary
Zhejiang Medicine has signed a supply contract with Hospira, an American specialty pharmaceutical and medication delivery company. Under the agreement, Zhejiang Medicine will provide Hospira vancomycin hydrochloride raw materials from April 30, 2008 to Dec. 31, 2017, with an expected total amount of $120 million. Taking into consideration the fluctuating Chinese yuan renminbi and U.S. dollar exchange rate, both sides have decided on the May 1, 2007 rate of $1 to 7.7 yuan as a benchmark. However, if the fluctuation exceeds 10 percent and lasts 90 days, both sides will adjust the value according to the new exchange rate at that point in time. (Click her for more - Chinese language)
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.